Artelo Biosciences has expanded into the lucrative glaucoma market with a fully funded clinical trial, showcasing its multi-platform pipeline addressing significant health issues. The company's advanced programs in oncology support and pain management, alongside favorable regulatory conditions, enhance its long-term investment appeal, attracting potential pharmaceutical partnerships as Phase 2 data show promise.
Artelo's study of ART27.13 for glaucoma, funded by Glaucoma UK, aims to assess its potential to lower intraocular pressure. Enrollment is expected in Q2 2026, expanding ART27.13’s therapeutic utility beyond current cancer applications, which could enhance shareholder value.
